Study guide
10.4 Collaborative Drug Therapy Management
Massachusetts MPJE Pharmacy Jurisprudence Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Federal Drug Law & Regulatory Foundations
1.1 Federal Acts & Agencies 1.2 Drug Supply Chain Security & Adulteration/Misbranding 1.3 Poison Prevention & Special Packaging Standards
2 Chapter 2: Federal Controlled Substances Act (CSA) Governance
2.1 CSA Scheduling, Registration & Ordering 2.2 Controlled Substance Inventory, Theft & Disposal 2.3 Corresponding Responsibility & DEA Red Flags
3 Chapter 3: Massachusetts Board Authority, Licensure & Continuing Education
3.1 Board of Registration in Pharmacy: Structure & Enforcement 3.2 Pharmacist Licensure, Reciprocity & Renewal 3.3 Continuing Education Requirements
4 Chapter 4: Massachusetts Pharmacy Personnel & Supervision
4.1 Pharmacy Interns: Licensure, Hours & Preceptors 4.2 Pharmacy Technician Licensure Tiers & Scope 4.3 Supervisory Ratios & Direct Supervision 4.4 Manager of Record: Duties, Appointment & Reporting
5 Chapter 5: Prescription Validity, Prescriber Authority & Opioid Limits
5.1 Elements of a Valid Massachusetts Prescription 5.2 Prescriber Authority & the Massachusetts Controlled Substances Registration 5.3 The Massachusetts Electronic Prescribing Mandate 5.4 M.G.L. c. 94C, Massachusetts Schedules & Prescription Validity Windows 5.5 Opioid Prescribing Limits & Partial Fill Rights
6 Chapter 6: Refills, Transfers, Recordkeeping & Emergency Dispensing
6.1 Refill Limits, Sequential Schedule II Prescriptions & Partial Fills 6.2 Prescription Transfers & Pharmacy Recordkeeping 6.3 Out-of-State Prescriptions 6.4 Emergency Dispensing: Oral Schedule II Orders & Schedule VI Emergency Supplies
7 Chapter 7: Product Selection, Labeling & Patient Care Standards
7.1 Mandatory Interchange & the Massachusetts List of Interchangeable Drug Products 7.2 Container Labeling, MedGuides & Patient Package Inserts 7.3 Patient Counseling, Profiles & Drug Utilization Review 7.4 Pharmacist Administration of Drugs & Vaccines 7.5 Returning, Reusing & Disposing of Dispensed Drugs
8 Chapter 8: MassPAT, Nonprescription Products, Public Health & Privacy
8.1 MassPAT: Prescription Monitoring Program Query & Reporting 8.2 Naloxone, Syringes & Standing Orders 8.3 Patient Privacy (HIPAA) & Massachusetts Privacy Rules 8.4 Nonprescription, Behind-the-Counter & Restricted OTC Products
9 Chapter 9: Pharmacy Facilities, Security, Automation & Quality
9.1 Pharmacy Licensure, Facilities & Required References 9.2 Continuous Quality Improvement & Quality Related Events 9.3 Pharmacy Practice Automation & Automated Dispensing Devices 9.4 Security, Delivery, Central Fill & Non-Resident Practice
10 Chapter 10: Compounding, Hazardous Drugs & Expanded Pharmacist Practice
10.1 Non-Sterile Compounding: USP <795> & the Massachusetts Overlay 10.2 Sterile Compounding: USP <797> & the Massachusetts Overlay 10.3 Hazardous Drugs & USP <800> 10.4 Collaborative Drug Therapy Management
11 Chapter 11: The MPJE Blueprint, Delivery & Scoring
11.1 How the MPJE Is Built, Delivered and Scored
10.4 Collaborative Drug Therapy Management
Key Takeaways Explain This Topic AI
Collaborative drug therapy management in Massachusetts has its own regulatory chapter, 247 CMR 16.00, and is distinct from the statewide standing orders discussed in section 8.2.
A collaborative agreement lets a pharmacist manage a patient's drug therapy — initiating, modifying, monitoring or discontinuing therapy — within written protocols agreed with a supervising physician.
A collaborative agreement is a delegation of clinical management to a named pharmacist for identified patients; a standing order is a prescription for a defined population that any qualified pharmacist may act on.
Nothing in a collaborative agreement moves the acts that regulation reserves to a pharmacist or that it prohibits to technicians, including drug utilization review, clinical conflict resolution and final dispensing process validation.
Read the current text of 247 CMR 16.00 and the Board's policies for the required content, approval route and record obligations of an agreement before relying on any summary.
Last updated: August 2026
Collaborative Drug Therapy Management
Massachusetts gives collaborative practice its own chapter of the Board's regulations: 247 CMR 16.00, Collaborative Drug Therapy Management . Candidates who look for it inside the professional practice standards chapter will not find it.
What Collaborative Drug Therapy Management Is
Under a collaborative drug therapy management (CDTM) agreement , a supervising physician delegates to a pharmacist the authority to manage a patient's drug therapy within a written protocol . Depending on the protocol, management can include:
- initiating drug therapy;
- modifying a dose, dosage form, route, frequency or duration;
- ordering and interpreting laboratory tests relevant to the therapy being managed;
- monitoring the patient's response and adverse effects; and
discontinuing therapy.
The defining feature is that the pharmacist is exercising clinical judgement about the patient's therapy , not simply dispensing what someone else decided.
CDTM Is Not a Standing Order
These two mechanisms are constantly confused, and telling them apart is a reliable exam point.
- Collaborative drug therapy management Statewide standing order
- Regulatory home 247 CMR 16.00 Statutory authority such as M.G.L. c. 94C, § 19E, plus DPH-issued orders
Who is authorised A named pharmacist (or pharmacists) party to the agreement Any qualified pharmacist in the Commonwealth
Which patients Identified patients of the collaborating practitioner A defined population meeting the order's criteria
What it authorises Ongoing management of drug therapy within a protocol Dispensing a defined product without an individual prescription
Typical example Anticoagulation, diabetes or hypertension management clinics Naloxone dispensing
Important
The question to ask is whether the pharmacist is managing therapy or dispensing a product . A pharmacist who adjusts a warfarin dose based on an INR is doing CDTM. A pharmacist who hands out naloxone to a member of the public is acting on a standing order. The first requires an agreement naming that pharmacist; the second does not.
Structure of an Agreement
Collaborative practice regulation across jurisdictions consistently requires an agreement to be written , to identify the parties , to define the scope with precision, and to be reviewed periodically . In practice an agreement addresses:
- the identity and credentials of the collaborating practitioner and pharmacist;
- the patients or conditions covered;
- the drugs or drug categories covered and any excluded categories;
- the specific functions delegated, and their limits;
- the documentation the pharmacist must make and where it goes in the medical record;
- the communication required back to the practitioner, and its timing;
- the circumstances requiring referral back to the practitioner; and
the review, renewal and termination arrangements.
Warning
Read the current regulation for the specifics. The required content of an agreement, the approval or filing route, any pharmacist experience or training prerequisites, the permitted settings, and the record retention period are all set by the current text of 247 CMR 16.00 and the Board's policies, and Massachusetts has revised its collaborative practice framework more than once. Do not carry forward a specific figure from a commercial study aid; verify it against the regulation as it stands when you sit the exam.
What CDTM Does Not Change
A collaborative agreement expands what a pharmacist may do. It does not move any boundary elsewhere:
Technicians are unaffected. 247 CMR 8.02(6)(d) and 8.04(4)(e) prohibit every technician tier from administering medications or vaccines, performing drug utilization review, conducting clinical conflict resolution, contacting prescribers about therapy clarification or modification, counselling patients, and performing final dispensing process validation. No agreement can delegate those to a technician.
Registration still applies. A pharmacist managing therapy under an agreement is still working within a licensed pharmacy subject to 247 CMR, and any controlled substance involved still engages the MCSR, PMP and c. 94C requirements.
Documentation still applies. Pharmacy records are retained for at least two years under 247 CMR 9.05, and CDTM documentation belongs in both the pharmacy record and the patient's medical record as the agreement specifies.
The supervisory ratios still apply. A pharmacist running a CDTM clinic is still the pharmacist for ratio purposes under 247 CMR 8.06(3).
Continuing Education
There is no CDTM-specific continuing education allocation in 247 CMR 4.03. The annual requirements that do attach to particular activities are sterile compounding (5 hours) , complex non-sterile compounding (3 hours) and pharmacy law (2 hours) , plus 1 hour on immunizations per two-year cycle for those who oversee or administer vaccines. A pharmacist practising under a collaborative agreement should nonetheless expect the agreement itself to specify competence requirements.
Worked Traps
A pharmacist not named in the agreement adjusts a dose under a colleague's CDTM protocol. Not authorised — CDTM authority runs to the pharmacists party to the agreement, unlike a standing order.
A certified pharmacy technician telephones a physician to propose a dose change under the clinic protocol. Violation — contacting a prescriber about therapy modification is prohibited to technicians regardless of any agreement.
A pharmacist relies on a five-year-old summary of Massachusetts collaborative practice requirements. Risky — verify against the current 247 CMR 16.00.